Literature DB >> 8105597

Partial agonists, full agonists, antagonists: dilemmas of definition.

D Hoyer1, H W Boddeke.   

Abstract

The absence of selective antagonists makes receptor characterization difficult, and largely dependent on the use of agonists. However, there has been considerable debate as to whether certain drugs acting at G protein-coupled receptors are better described as agonists, partial agonists or antagonists. Indeed many agonists tend to display differences in intrinsic activity, depending on the preparation used to study receptor pharmacology. It has been argued that variations in intrinsic activity of drugs, may be a reflection of receptor subtypes rather than varying degrees of receptor-effector coupling. However, it has often been overlooked that classical receptor theory predicts that a drug acting at a given receptor type can display a range of intrinsic activities depending on the extent of receptor reserve. Furthermore, because any receptor can couple to different effector systems, different degrees of intrinsic activity may be observed for a given drug. Daniel Hoyer and Hendrikus Boddeke review recent data which provide explanations for why drugs display such variations in intrinsic activity.

Mesh:

Substances:

Year:  1993        PMID: 8105597     DOI: 10.1016/0165-6147(93)90129-8

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  45 in total

1.  The dopamine D3 receptor partial agonist CJB090 and antagonist PG01037 decrease progressive ratio responding for methamphetamine in rats with extended-access.

Authors:  Laura Orio; Sunmee Wee; Amy H Newman; Luigi Pulvirenti; George F Koob
Journal:  Addict Biol       Date:  2010-04-29       Impact factor: 4.280

2.  In vivo electrophysiological and neurochemical effects of the selective 5-HT1A receptor agonist, F13640, at pre- and postsynaptic 5-HT1A receptors in the rat.

Authors:  Laia Lladó-Pelfort; Marie-Bernadette Assié; Adrian Newman-Tancredi; Francesc Artigas; Pau Celada
Journal:  Psychopharmacology (Berl)       Date:  2011-12-03       Impact factor: 4.530

3.  Preferential in vivo action of F15599, a novel 5-HT(1A) receptor agonist, at postsynaptic 5-HT(1A) receptors.

Authors:  L Lladó-Pelfort; M-B Assié; A Newman-Tancredi; F Artigas; P Celada
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

4.  Pharmacological blockade of dopamine D2 receptors by aripiprazole is not associated with striatal sensitization.

Authors:  Beryl Koener; Stéphanie Goursaud; Morgane Van De Stadt; André-Guilhem Calas; Anne P Jeanjean; Jean-Marie Maloteaux; Emmanuel Hermans
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-01       Impact factor: 3.000

5.  Spatial coordination of kindlin-2 with talin head domain in interaction with integrin β cytoplasmic tails.

Authors:  Kamila Bledzka; Jianmin Liu; Zhen Xu; H Dhanuja Perera; Satya P Yadav; Katarzyna Bialkowska; Jun Qin; Yan-Qing Ma; Edward F Plow
Journal:  J Biol Chem       Date:  2012-05-30       Impact factor: 5.157

6.  The partial D2-like dopamine receptor agonist terguride acts as a functional antagonist in states of high and low dopaminergic tone: evidence from preweanling rats.

Authors:  Sanders A McDougall; Rita M Hernandez; Carmela M Reichel; Cristal M Farley
Journal:  Psychopharmacology (Berl)       Date:  2004-11-18       Impact factor: 4.530

7.  [3H]-L-2-amino-4-phosphonobutyrate labels a metabotropic glutamate receptor, mGluR4a.

Authors:  L Eriksen; C Thomsen
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

8.  Atypical antipsychotics and inverse agonism at 5-HT2 receptors.

Authors:  Laura C Sullivan; William P Clarke; Kelly A Berg
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

9.  Activity of adenosine diphosphates and triphosphates on a P2Y(T) -type receptor in brain capillary endothelial cells.

Authors:  J Simon; P Vigne; K M Eklund; A D Michel; A M Carruthers; P P Humphrey; C Frelin; E A Barnard
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

10.  Inactivation of JAK2/STAT3 signaling axis and downregulation of M1 mAChR cause cognitive impairment in klotho mutant mice, a genetic model of aging.

Authors:  Seok-Joo Park; Eun-Joo Shin; Sun Seek Min; Jihua An; Zhengyi Li; Yoon Hee Chung; Ji Hoon Jeong; Jae-Hyung Bach; Seung-Yeol Nah; Won-Ki Kim; Choon-Gon Jang; Yong-Sun Kim; Yo-Ichi Nabeshima; Toshitaka Nabeshima; Hyoung-Chun Kim
Journal:  Neuropsychopharmacology       Date:  2013-02-06       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.